Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary

Hiroshi Tsuda, Kiyoshi Ito, Nobuo Yaegashi, Akira Hirasawa, Tamotsu Sudo, Tsunekazu Kita, Yoshito Terai, Junzo Kigawa, Toru Sugiyama, Daisuke Aoki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphateYbinding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary. Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinumbased primary chemotherapy followed by primary surgery. Results: Adenosine triphosphateYbinding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2- negative cases (median survival time, 1175 vs 1257 days; P = 0.24). Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

Original languageEnglish
Pages (from-to)794-797
Number of pages4
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number5
DOIs
Publication statusPublished - Jul 1 2010
Externally publishedYes

Fingerprint

Clear Cell Adenocarcinoma
Ovary
Drug Therapy
Adenosine
Survival
Proteins
Adenosine Triphosphate
Staining and Labeling

Keywords

  • ABC transporter
  • Clear cell adenocarcinoma
  • Prognosis

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. / Tsuda, Hiroshi; Ito, Kiyoshi; Yaegashi, Nobuo; Hirasawa, Akira; Sudo, Tamotsu; Kita, Tsunekazu; Terai, Yoshito; Kigawa, Junzo; Sugiyama, Toru; Aoki, Daisuke.

In: International Journal of Gynecological Cancer, Vol. 20, No. 5, 01.07.2010, p. 794-797.

Research output: Contribution to journalArticle

Tsuda, Hiroshi ; Ito, Kiyoshi ; Yaegashi, Nobuo ; Hirasawa, Akira ; Sudo, Tamotsu ; Kita, Tsunekazu ; Terai, Yoshito ; Kigawa, Junzo ; Sugiyama, Toru ; Aoki, Daisuke. / Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 5. pp. 794-797.
@article{05d6701ac5f946898bc7aac2a943f0e0,
title = "Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary",
abstract = "Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphateYbinding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary. Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinumbased primary chemotherapy followed by primary surgery. Results: Adenosine triphosphateYbinding cassette superfamily F2 expression was detected in 118 (71.5{\%}) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3{\%} (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7{\%} vs 34.8{\%}, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2- negative cases (median survival time, 1175 vs 1257 days; P = 0.24). Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.",
keywords = "ABC transporter, Clear cell adenocarcinoma, Prognosis",
author = "Hiroshi Tsuda and Kiyoshi Ito and Nobuo Yaegashi and Akira Hirasawa and Tamotsu Sudo and Tsunekazu Kita and Yoshito Terai and Junzo Kigawa and Toru Sugiyama and Daisuke Aoki",
year = "2010",
month = "7",
day = "1",
doi = "10.1111/IGC.0b013e3181a835fc",
language = "English",
volume = "20",
pages = "794--797",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary

AU - Tsuda, Hiroshi

AU - Ito, Kiyoshi

AU - Yaegashi, Nobuo

AU - Hirasawa, Akira

AU - Sudo, Tamotsu

AU - Kita, Tsunekazu

AU - Terai, Yoshito

AU - Kigawa, Junzo

AU - Sugiyama, Toru

AU - Aoki, Daisuke

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphateYbinding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary. Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinumbased primary chemotherapy followed by primary surgery. Results: Adenosine triphosphateYbinding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2- negative cases (median survival time, 1175 vs 1257 days; P = 0.24). Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

AB - Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphateYbinding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary. Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinumbased primary chemotherapy followed by primary surgery. Results: Adenosine triphosphateYbinding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2- negative cases (median survival time, 1175 vs 1257 days; P = 0.24). Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

KW - ABC transporter

KW - Clear cell adenocarcinoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77956821073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956821073&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181a835fc

DO - 10.1111/IGC.0b013e3181a835fc

M3 - Article

VL - 20

SP - 794

EP - 797

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -